ure 3 b) by using Equations ( 1) and ( 2) (for all equations, see the Supporting Information). Binding data for various concentrations of 8 were then fitted with the aid of a set of four equilibrium equations [Eqs. ( 3)-( 6)] and three equations of mass conservation [Eqs. ( 7)-( 9)] in order to obta
Development of a CD28 Receptor Binding-Based Screen and Identification of a Biologically Active Inhibitor
β Scribed by Chung-Her Jenh; Meng Zhang; Maria Wiekowski; Jimmy C. Tan; Xue-Dong Fan; Vinod Hegde; Mahesh Patel; Robert Bryant; Satwant K. Narula; Paul J. Zavodny; Chuan-Chu Chou
- Publisher
- Elsevier Science
- Year
- 1998
- Tongue
- English
- Weight
- 152 KB
- Volume
- 256
- Category
- Article
- ISSN
- 0003-2697
No coin nor oath required. For personal study only.
β¦ Synopsis
CD28 is a T-cell costimulatory receptor which plays a pivotal role in antigen-induced T-cell response. We have developed a cell-free and scintillation-proximity assay-based screen to search for molecules that inhibit ligand binding to CD28. The assay was shown to be versatile and adaptable to automation for high-throughput screening. Using this assay, we identified an inhibitor of CD28, NP2214. The inhibitor was shown to be active in vitro by suppressing IL-2 synthesis and proliferation of peripheral blood mononuclear cells in response to CD28 costimulation. We also demonstrated the additive effects of NP2214 and cyclosporine A which act mechanistically distinctly in inhibiting costimulation-induced IL-2 synthesis.
π SIMILAR VOLUMES
The effect of RGD-sequence-containing pentapeptides and monoclonal antibodies (MAbs) against the adhesion molecules CDI la-dCD18, ICAM-I (CD54) and CD2 on the binding and cytotoxicity of endogenous (freshly purified) and IL-2 -I t' imulated CD3-negative N K cells has been studied. Antibody to CD18 e